AMRN

Amarin Corp Plc

11.75

USD

+0.01

+0.09%

Nov 10, 15:59 UTC -5

Closed

After-Market

11.77

+0.02

+0.13%

Amarin Corp Plc (AMRN) Profile

Amarin Corp Plc Profile

About

Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels. The FDA approved Vascepa to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe under the tradename of Vazkepa. It has initiated various promotional activities and direct-to-consumer programs as well as expanded its salesforce to support promotion of Vascepa's expanded label. A generic version of Vascepa has been launched for elevated TG levels.

Info & Links

CEO

Aaron Berg

Headquarters

ONE CENTRAL PLAZA, 8TH FLOOR, 36 DAME STREET
DUBLIN, L2 D02 K7K5, IRELAND

Auditor

Ernst & Young LLP

Share holders

275

Employees

Amarin Corp Plc Statistics

Valuation Measures

Market Capitalization²

494.63M

Enterprise Value

337.92M

Enterprise Value/EBITDA(ttm)

-11.49

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

1.47

Price to Book(mrq)

0.58

Price to Cash(ytd)

33.94

Profitability

Gross Margin(ttm)

40.72%

Operating Margin(ttm)

-1.31%

Profit Margin(ttm)

-10.82%

Return on Equity(ttm)

-0.52%

Return on Invested Capital(ttm)

-4.27%

Return on Assets(ttm)

-0.36%

Income Statement

Revenue(ttm)

176.11M

Revenue Per Share(ttm)

Gross Profit(ttm)

72.11M

EBITDA(ttm)³

-29.41M

Net Income Available to Common(ttm)

-19.14M

Diluted EPS(ttm)

-0.96

Share Statistics

Beta (5Y Monthly)

0.81

52-Week Change

-25.21%

S&P 500 52-Week Change

16.37%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

Dividend Yield

0.00%

Float⁴

20.23M

% Held by Insiders

4.21%

% Held by Institutions

22.25%

Balance Sheet

Total Cash(mrq)

323.58M

Total Cash Per Share(mrq)

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.50%

Quick Ratio(mrq)

2.59%

Book Value Per Share(mrq)

21.08

Cash Flow

Operating Cash Flow Per Share(ytd)

1.04

Free Cash Flow(ytd)

22.21M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.